Liquidia Technologies (NASDAQ:LQDA) Director Paul B. Manning Sells 188,232 Shares

Key Points

• Paul Manning, a director at Liquidia Technologies, sold 188,232 shares of the company stock for a total of $5,198,967.84, reducing his ownership by nearly 20%.
• Liquidia Technologies reported a quarterly revenue increase of 141.5% year-over-year, though its earnings per share missed consensus estimates by $0.06.
• The company's stock received several upgrades from analysts, with a consensus rating of "Buy" and a target price of $32.11.

Liquidia Technologies, Inc. (NASDAQ:LQDA - Get Free Report) Director Paul B. Manning sold 188,232 shares of the company's stock in a transaction on Friday, August 29th. The shares were sold at an average price of $27.62, for a total transaction of $5,198,967.84. Following the transaction, the director owned 759,096 shares of the company's stock, valued at approximately $20,966,231.52. The trade was a 19.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Liquidia Technologies Price Performance

Shares of LQDA stock traded up $0.01 during mid-day trading on Friday, reaching $28.85. The company's stock had a trading volume of 1,409,821 shares, compared to its average volume of 3,019,348. Liquidia Technologies, Inc. has a 1-year low of $8.75 and a 1-year high of $29.94. The company has a market cap of $2.48 billion, a P/E ratio of -16.97 and a beta of 0.22. The company has a debt-to-equity ratio of 9.84, a quick ratio of 2.41 and a current ratio of 2.49. The firm's 50-day moving average is $20.43 and its two-hundred day moving average is $16.78.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.06). Liquidia Technologies had a negative net margin of 732.17% and a negative return on equity of 232.96%. The business had revenue of $8.84 million during the quarter, compared to analyst estimates of $3.90 million. The business's revenue for the quarter was up 141.5% on a year-over-year basis. On average, research analysts predict that Liquidia Technologies, Inc. will post -1.51 earnings per share for the current year.

Institutional Investors Weigh In On Liquidia Technologies

A number of hedge funds have recently added to or reduced their stakes in LQDA. Wells Fargo & Company MN grew its holdings in Liquidia Technologies by 69.1% during the 4th quarter. Wells Fargo & Company MN now owns 30,020 shares of the company's stock worth $353,000 after acquiring an additional 12,267 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Liquidia Technologies during the 4th quarter worth about $218,000. MetLife Investment Management LLC grew its holdings in Liquidia Technologies by 14.8% during the 4th quarter. MetLife Investment Management LLC now owns 38,520 shares of the company's stock worth $453,000 after acquiring an additional 4,969 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Liquidia Technologies by 31.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 24,623 shares of the company's stock worth $290,000 after acquiring an additional 5,945 shares during the last quarter. Finally, Tudor Investment Corp ET AL bought a new stake in Liquidia Technologies during the 4th quarter worth about $454,000. Institutional investors own 64.54% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Bank of America dropped their price objective on shares of Liquidia Technologies from $25.00 to $23.00 and set a "buy" rating for the company in a research note on Wednesday, June 11th. Scotiabank increased their price objective on shares of Liquidia Technologies from $36.00 to $37.00 and gave the company a "sector outperform" rating in a research note on Wednesday, May 28th. HC Wainwright upped their target price on shares of Liquidia Technologies from $29.00 to $35.00 and gave the stock a "buy" rating in a report on Wednesday, May 28th. Needham & Company LLC upped their target price on shares of Liquidia Technologies from $32.00 to $36.00 and gave the stock a "buy" rating in a report on Tuesday, August 12th. Finally, Oppenheimer set a $13.00 target price on shares of Liquidia Technologies and gave the stock an "underperform" rating in a report on Monday, May 19th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Liquidia Technologies currently has an average rating of "Buy" and a consensus price target of $32.11.

Liquidia Technologies Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).